Shalini Andersson, PhDChief Scientist New Therapeutic Modalities at AstraZeneca
Shalini is currently the Chief Scientist and Head of Oligonucleotide Discovery at AstraZeneca. Shalini has broad experience in Pharmaceutical research as well as strategic and management roles. Shalini drives several collaborations with external partners and is also involved in several academic collaborations across the globe. Prior to this role, Shalini held several leadership roles in Drug Metabolism & Pharmacokinetics and Medicinal Chemistry. Shalini received her PhD in 1989 at the University of Linköping, Sweden and has held various research and teaching positions at the University of Linköping prior to moving to industry. She is the author or co-author of over 50 peer reviewed articles, 2 book chapters and 5 patents.